Stephens raised the firm’s price target on Natera (NTRA) to $235 from $197 and keeps an Overweight rating on the shares after the company reported “another strong beat.” The firm continues to view Natera as “one of the most attractive organic growth stories” within diagnostics, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: